Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)
Code : 9345-354102      Publish Date : Sunday, March 4, 2018 Visit : 1865

Intl. Congress form | International Congress Report | International Congress Report For Faculty | The report of Congress :European Society of Ophthalmology (SOE) 2017 Congress by Dr. Farzad Pakdel

The report of Congress :European Society of Ophthalmology (SOE) 2017 Congress by Dr. Farzad Pakdel
The report of Congress :European Society of Ophthalmology (SOE) 2017 Congress by Dr. Farzad Pakdel
Application Code :
762-0118-0042
 
Created Date : Wednesday, June 7, 2017-13:29 13:29:20Update Date : Sunday, March 4, 2018-08:38 08:38:10
IP Address : 194.225.214.3Submit Date : Sunday, March 4, 2018-08:39 08:39:12Email : fapakdel@gmail.com
Personal Information
Name : Farzad
Surname : Pakdel
School/Research center : School of Medicine
If you choose other, please name your Research center :  
Position : Assistant professor
Tel : +98-21-554211
Information of Congress
Title of the Congress : European Society of Ophthalmology (SOE) 2017 Congress
Title of your Abstract : "Disease modifying drugs in sclerosing orbital inflammatory syndrome: concept and application"
Destination Country : Spain
From : Saturday, June 10, 2017
To : Tuesday, June 13, 2017
Abstract(Please copy/paste the abstract send to the congress) : FP-OPL-020 Disease modifying drugs in sclerosing orbital inflammatory syndrome: concept and application Pakdel F.1, Pirmarzdashti N.2, Haghighi A.3 1Farabi Hospital, Eye Research Center, Tehran University of Medical Sciences, Ophthalmic Plastic & Reconstructive Surgery Department, Tehran, Iran, Islamic Republic of, 2Farabi Hospital, Eye Research Center, Tehran, Iran, Islamic Republic of, 3Rassoul Akram Hospital, Iran University of Medical Sciences, Rheumatology Department, Tehran, Iran, Islamic Republic of Purpose: To describe application of combination of anti-TNF- alpha agents and azathioprine in patients with resistant progressive sclerosing orbital inflammatory syndrome (sOIS). We propose the concept of disease modifying anti-orbital inflammatory drugs (DMAODs) and disease activity in the management of sOIS. Method: In a prospective interventional study we used anti-TNF-a in biopsy proven patients with progressive sIOIS. Disease activity was defined by presence of any of the criteria including, progressive decrease in visual function that could not be otherwise explained; orbital pain; peri-orbital swelling; progressive proptosis; emergence or worsening of limitation in extra-ocular motility; and progressive eyelid retraction. Results: Five patients with sIOIS were included. Mean age of them was 32. (range 19-53) years. Three had unilateral and two had bilateral involvement. Four had diffuse orbital involvement pattern and progressive worsening of visual functions, reduced extra-ocular motility and proptosis and one had bilateral lacrimal gland involvement. The disease was successfully controlled following the regimen of infliximab, adalimumab or etanercept combined with low dose prednisolone and azathioprine. Mean follow up of patients was 21.3 (range: 8-66) months. No significant drug adverse effect was detected in follow up time. Conclusion: A regimen including etanercept, infliximab or adalimumab combined with azathioprine and low dose corticosteroid was effective in recalcitrant sIOIS cases and could change the course of the disease. We propose that this regimen could be considered as biological disease modifying anti-orbital inflammatory drugs (DMAODs) regimen and can be regarded the mainstay of treatment of sOIS.
Keywords of your Abstract : Disease Modifying Drug, orbital inflammatory syndrome
Acceptance Letter : http://gsia.tums.ac.ir/images/UserFiles/38007/Forms/762/letter of acceptance SOE 2017 Free Paper Presentation acceptance FPOPL020 ACTION REQUIRED_5.pdf
The presentation : Oral
The Cover of Abstract book : http://gsia.tums.ac.ir/images/UserFiles/38007/Forms/762/cover Abstract book SOE 2017_7.pdf
Published abstract in the abstract book with the related code : http://gsia.tums.ac.ir/images/UserFiles/38007/Forms/762/SOE2017-AbstractBook_1.pdf
Where has your abstract been indexed? : none
If you choose other, please name :  
The Congress Reporting Form
How many volunteers were present at the Congress? : approximately 10,000. Mostly from United kingdom, france, Spain, Netherland, Germany, Italy, United states, China.
Delegates from which countries presented in the congress? : From all of the world: European,UK, north and south America, Asia, Austria
Were the delegates of any other organizations present in the congress? : Yes
If yes, please write the names of the organizations in the box : ophthalmology Academies: AAO, APAO, SOE,AOS
What were the responses to your talking points? Were specific questions or concerns raised? : New modalities for management of a challenging disease, Yes we had discussions.
If you met staff members, please list their full names & positions. : no
Please inform us if there are any follow up actions we need to talk with the members of the congress : encouragements.
Your experiences about the travel processes(Providing ticket, accommodation,...) : Actually, visa and finding credit cards for hotel reservation and congress registration were difficult and time consuming process. Fortunately flight ticket reservation was much easier than the proceedings.
Please give a briefing of your own observations and outcomes of the congress: : it was a Good opportunity for delivering my research idea and results about a challenging disease (sIOIS). Good to receive comments from other colleagues and see their researches and also updates in my field.